Sino Biopharmaceutical (HKG:1177) subsidiary Chia Tai Tianqing Pharmaceutical Group obtained an exclusive sub-licensable license to register, develop, produce, and commercialize Wuhan YZY Biopharma's (HKG:2496) cancer drug in mainland China.
The drug M701 is indicated for the treatment of malignant pleural effusion (MPE) and malignant ascites (MA) caused by tumors. It is in stage 3 clinical trials and has shown good results by inciting the immune system to kill cancer cells in abdominal and chest cavities.
Chia Tai will pay 315 million yuan upfront, plus up to 700 million yuan in sales milestone payments, and tiered royalties to YZY Biopharma, a Tuesday Hong Kong bourse filing said.
The pharmaceutical company's shares closed nearly 7% lower on Tuesday.
Price (HKD): $3.85, Change: $-0.28, Percent Change: -6.78%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。